Ovarian Cancer Trial, Not Yet Recruiting NCT05921149 Sponsor: Endeavor Health Condition: Ovarian Cancer
Back to Ovarian Cancer

Ovarian Cancer Trial, Not Yet Recruiting

NCT05921149
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Adults aged 18 years or older.
  • People with advanced ovarian, fallopian tube, or primary peritoneal cancer who are considered suitable for chemotherapy given before surgery, or people whose cancer has come back at least 6 months after finishing their last platinum-based chemotherapy treatment.
  • People who are reasonably active and able to care for themselves, rated on a standard scale as 0, 1, or 2 (confirm with trial site).
  • People whose blood counts show the bone marrow is working well enough — specifically, a certain level of infection-fighting cells and platelets in the blood (confirm with trial site for exact values).
  • People whose kidneys are working well enough, based on a blood test result within an acceptable range.
  • People whose liver is working well enough, based on blood test results for liver enzymes and bilirubin within acceptable ranges.
  • People with a body mass index (BMI) of 19 or above.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who are malnourished or have a BMI below 19.
  • People with an active eating disorder, identified through a nutrition screening done before enrolment.
  • People who have diabetes that is managed with medication, whether insulin or other diabetes medicines (note: people whose diabetes is controlled by diet alone, without any medication, are not excluded).
  • People who are allergic to any ingredient in the fasting mimicking diet (FMD) used in the trial.
  • People whose ovarian, fallopian tube, or primary peritoneal cancer came back within 6 months of finishing their last platinum-based chemotherapy — this is known as platinum-resistant disease.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Mary T Jenkins Vogel, MD, Endeavor Health

Phone: (847) 570-2109

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Endeavor Health
Registry
ClinicalTrials.gov
Start date
25 May 2024
Est. completion
1 June 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

To determine whether the combination of standard of care platinum-taxane chemotherapy with a FMD compared to a regular diet is associated with decreased gastrointestinal (GI) toxicity in advanced and recurrent ovarian cancer patients.; To determine whether the combination of standard of care platinum-taxane chemotherapy with a FMD compared to a regular diet is associated with decreased neurotoxicity in advanced and recurrent ovarian cancer patients.; To determine whether the combination of standard of care platinum-taxane chemotherapy with a FMD compared to a regular diet is associated with de...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov